Therapy Areas: Infectious Diseases
Valneva secures USD32m IXIARO vaccine contract with US DoD
25 September 2023 - Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) announced on Monday that it has signed a new contract valued at a minimum of USD32m with the US Department of Defense ...
MicuRx Pharmaceuticals' Contezolid and Contezolid acefosamil receive Fast Track Designation and US FDA QIDP
25 September 2023 - MicuRx Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced on Friday that it has received Qualified Infectious Disease Product (QIDP) and Fast Track Designation ...
Scancell reports positive data from Phase 2 SCOPE trial for SCIB1 cancer vaccine in advanced melanoma
19 September 2023 - Clinical-stage biopharmaceutical company Scancell Holdings plc (AIM: SCLP) has shared promising results from the initial stage of its Phase 2 SCOPE trial involving SCIB1 in combina...
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
19 September 2023 - ResVita Bio, a US-based synthetic biology startup, announced on Monday that it has received a USD250,000 Phase 1 Small Business Innovation Research (SBIR) grant from the National I...
NanoString Technologies introduces GeoMx IO Proteome Atlas (IPA) For spatial proteomics
13 September 2023 - NanoString Technologies (NASDAQ: NSTG), a provider of life science tools for discovery and translational research, announced on Wednesday that it has introduced the GeoMx IO Proteo...
Replicate Bioscience begins phase one trial of RBI-4000 vaccine
13 September 2023 - Replicate Bioscience, a clinical-stage company, announced on Tuesday that it has dosed its first subject in a phase one trial of RBI-4000 vaccine intended to prevent rabies.This tr...